Skip to main content

Advertisement

Table 1 Baseline demographic and disease characteristics

From: Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

  All patients with AML-MRC (N = 262) LDAC-preselected patients with AML-MRC (n = 160)
  Azacitidine (n = 129) CCR (n = 133) Azacitidine (n = 81) LDAC (n = 79)
Age (years), median (min, max) 76 (64, 90) 75 (65, 87) 76 (64, 90) 75 (65, 87)
Age ≥ 75 years, n (%) 77 (60) 69 (52) 55 (68) 41 (52)
Male gender, n % 81 (63) 78 (59) 42 (52) 43 (54)
Prior history of MDS*, n (%) 44 (34) 35 (26) 32 (40) 20 (25)
ECOG PS, n (%)
0–1 94 (73) 104 (78) 56 (69) 64 (81)
2 35 (27) 29 (22) 25 (31) 15 (19)
Cytogenetic risk, n (%)
Intermediate 63 (49) 61 (46) 47 (58) 33 (42)
Poor 66 (51) 72 (54) 34 (42) 46 (58)
No. of dysplastic lineages, n (%)
0–1 57 (44) 52 (39) 36 (44) 35 (44)
2–3 72 (56) 81 (61) 45 (56) 44 (56)
% BM blasts, median (min, max) 65.0 (27, 99) 70.0 (26, 100) 66.0 (27, 99) 69.0 (31, 100)
Haematology, median (min, max)
ANC (109/L) 0.4 (0.0, 11.6) 0.3 (0.0, 8.7) 0.4 (0.0, 11.6) 0.3 (0.0, 8.7)
Platelets (109/L) 56 (3, 585) 55 (6, 244) 58 (7, 585) 55 (6, 244)
WBC (109/L) 3.2 (0.6, 26.5) 2.4 (0.4, 22.6) 2.6 (0.6, 26.5) 2.3 (0.4, 13.5)
Hgb (g/dL) 9.5 (5.0, 13.4) 9.3 (5.0, 14.4) 9.4 (5.0, 11.8) 9.4 (5.6, 14.4)
  1. *Based on local site reporting
  2. AML-MRC, AML with myelodysplasia-related changes; ANC, absolute neutrophil count; BM, bone marrow; CCR, conventional care regimens; ECOG PS, Eastern Cooperative Oncology Group performance status; Hgb, haemoglobin; LDAC, low-dose cytarabine; MDS, myelodysplastic syndromes; WBC, white blood cell count